Overview

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of Rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH).
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Rimonabant